Medical Technology Company Receives Notice of Allowance For CRRT Device: Stock Soars Over 60%

The recent advancement by Nuwellis, Inc., marked by a significant upsurge in its stock value, has drawn considerable attention. The company, a well-established name in the domain of fluid management solutions, witnessed a notable 67% increase in its share price, closing at $0.2230 following the announcement of receiving a Notice of Allowance for a patent application from the U.S. Patent and Trademark Office (USPTO). This development is centered around its pioneering pediatric Continuous Renal Replacement Therapy (CRRT) device, branded as Vivian™, which promises to enhance treatment modalities for critically ill children suffering from fluid overload conditions. $Nuwellis(NUWE.US)$